Call us 24/7

Clinical trials

Search our clinical trials

Cancer Treatment Centers of America® (CTCA) is committed to providing new and innovative treatments for our cancer patients whenever possible. This includes enrolling qualified patients in carefully selected clinical trials for cancer. Clinical trials are a key testing ground for determining the effectiveness and safety of new treatments and drugs for cancer and other diseases. Our doctors may recommend that cancer patients enroll in cancer clinical trials if they meet specific criteria. Cancer trials may offer patients access to treatment options that would otherwise be unavailable to them. Talk to your doctor about whether a cancer trial is a good option for you and ask about the risks and various requirements involved. Use the tool below to find a CTCA® clinical trial for your cancer type.

Filters

45 Clinical Trials

The purpose of this study is to evaluate whether copanlisib in combination with rituximab is superior to a placebo in combination with rituximab in prolonging progression free survival in some patients with relapsed indolent non-Hodgkin lymphoma.

The primary objectives will be to determine the efficacy of MT-3724 as monotherapy in subjects with relapsed or refractory DLBCL based on the overall response rate (ORR) by the revised Lugano Classification for lymphoma adjusted according to lymphoma response to immunomodulatory therapy criteria (LYRIC) hereinafter referred to as “revised Lugano Criteria” (Cheson et al, 2014, 2016).

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This randomized, phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned (recurrent) after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory).

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This phase I/II partially randomized trial studies the side effects and the best dose of ruxolitinib phosphate when given together with paclitaxel and carboplatin and to see how well they work in treating patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with recurrent platinum-resistant ovarian cancer.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a global, multi-center, randomized, double-blind, controlled phase 3 study in patients with newly diagnosed, stage III or IV non-mucinous epithelial ovarian, fallopian tube, or peritoneal cancer (collectively referred to as ovarian cancer).

The purpose of this study is to confirm the recommended phase II dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This study compares radiographic progression free survival (rPFS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with talazoparib plus enzalutamide versus enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.

The main purpose of this study is to compare the overall response rate (ORR) and overall survival (OS) of NKTR-214 combined with nivolumab to that of a tyrosine kinase inhibitor (TKI) monotherapy (sunitinib or cabozantinib) in intermediate and poor-risk participants with previously untreated advanced renal cell carcinoma (RCC).

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a phase 1/2, multi-center, open-label study designed to evaluate the safety and efficacy of LOXO-195 when administered orally to patients age ≥ 1 month and older with NTRK fusion cancers treated with a prior TRK inhibitor.